| Schedule of Segment Reporting Information, by Segment |
The tables below present information about reported segments, unallocated corporate operations as well as geographic information for the six months ended June 30, 2026 and 2025:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
|
For the six months ended June 30, |
|
(In thousands) |
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Revenue from services: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Diagnostics |
|
|
74,549 |
|
|
|
101,101 |
|
|
|
146,735 |
|
|
|
203,945 |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
74,549 |
|
|
$ |
101,101 |
|
|
$ |
146,735 |
|
|
$ |
203,945 |
|
Revenue from products: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
42,941 |
|
|
$ |
40,743 |
|
|
$ |
80,984 |
|
|
$ |
75,585 |
|
Diagnostics |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
42,941 |
|
|
$ |
40,743 |
|
|
$ |
80,984 |
|
|
$ |
75,585 |
|
Revenue from transfer of intellectual property and other: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
46,090 |
|
|
$ |
14,963 |
|
|
$ |
60,058 |
|
|
$ |
27,229 |
|
Diagnostics |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
46,090 |
|
|
$ |
14,963 |
|
|
$ |
60,058 |
|
|
$ |
27,229 |
|
Cost of revenue: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
25,101 |
|
|
$ |
25,022 |
|
|
$ |
47,399 |
|
|
$ |
47,836 |
|
Diagnostics |
|
|
58,462 |
|
|
|
82,383 |
|
|
|
114,604 |
|
|
|
166,901 |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
83,563 |
|
|
$ |
107,405 |
|
|
$ |
162,003 |
|
|
$ |
214,737 |
|
Gross margin: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
63,930 |
|
|
$ |
30,684 |
|
|
$ |
93,643 |
|
|
$ |
54,978 |
|
Diagnostics |
|
|
16,087 |
|
|
|
18,718 |
|
|
|
32,131 |
|
|
|
37,044 |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
80,017 |
|
|
$ |
49,402 |
|
|
$ |
125,774 |
|
|
$ |
92,022 |
|
Selling, general and administrative: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
13,916 |
|
|
$ |
13,197 |
|
|
$ |
28,121 |
|
|
$ |
25,907 |
|
Diagnostics |
|
|
26,574 |
|
|
|
33,369 |
|
|
|
52,725 |
|
|
|
71,325 |
|
Corporate |
|
|
12,434 |
|
|
|
13,031 |
|
|
|
20,685 |
|
|
|
21,451 |
|
|
|
$ |
52,924 |
|
|
$ |
59,597 |
|
|
$ |
101,531 |
|
|
$ |
118,683 |
|
Research and development: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
32,739 |
|
|
$ |
29,778 |
|
|
$ |
61,492 |
|
|
$ |
60,016 |
|
Diagnostics |
|
|
294 |
|
|
|
484 |
|
|
|
606 |
|
|
|
1,022 |
|
Corporate |
|
|
133 |
|
|
|
80 |
|
|
|
267 |
|
|
|
145 |
|
|
|
$ |
33,166 |
|
|
$ |
30,342 |
|
|
$ |
62,365 |
|
|
$ |
61,183 |
|
Amortization of intangible assets: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
16,436 |
|
|
$ |
16,415 |
|
|
$ |
32,869 |
|
|
$ |
32,525 |
|
Diagnostics |
|
|
2,533 |
|
|
|
3,029 |
|
|
|
5,066 |
|
|
|
6,779 |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
18,969 |
|
|
$ |
19,444 |
|
|
$ |
37,935 |
|
|
$ |
39,304 |
|
Other segment items: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
|
$ |
— |
|
Diagnostics |
|
|
(18,070 |
) |
|
|
— |
|
|
|
(18,070 |
) |
|
|
— |
|
Corporate |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
$ |
(18,070 |
) |
|
$ |
— |
|
|
$ |
(18,070 |
) |
|
$ |
— |
|
Segment operating loss: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
839 |
|
|
$ |
(28,706 |
) |
|
$ |
(28,839 |
) |
|
$ |
(63,470 |
) |
Diagnostics |
|
|
4,756 |
|
|
|
(18,164 |
) |
|
|
(8,196 |
) |
|
|
(42,082 |
) |
Corporate |
|
|
(12,567 |
) |
|
|
(13,111 |
) |
|
|
(20,952 |
) |
|
|
(21,596 |
) |
|
|
$ |
(6,972 |
) |
|
$ |
(59,981 |
) |
|
$ |
(57,987 |
) |
|
$ |
(127,148 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the three months ended June 30, |
|
|
For the six months ended June 30, |
|
|
|
2026 |
|
|
2025 |
|
|
2026 |
|
|
2025 |
|
Depreciation and amortization: |
|
|
|
|
|
|
|
|
|
|
|
|
Pharmaceutical |
|
$ |
18,511 |
|
|
$ |
18,142 |
|
|
$ |
36,770 |
|
|
$ |
35,930 |
|
Diagnostics |
|
|
3,883 |
|
|
|
4,885 |
|
|
|
7,810 |
|
|
|
10,584 |
|
Corporate |
|
|
15 |
|
|
|
— |
|
|
|
29 |
|
|
|
— |
|
|
|
$ |
22,409 |
|
|
$ |
23,027 |
|
|
$ |
44,609 |
|
|
$ |
46,514 |
|
Revenues: |
|
|
|
|
|
|
|
|
|
|
|
|
United States |
|
$ |
88,809 |
|
|
$ |
114,884 |
|
|
$ |
172,313 |
|
|
$ |
231,091 |
|
Ireland |
|
|
41,663 |
|
|
|
11,742 |
|
|
|
51,343 |
|
|
|
17,221 |
|
Chile |
|
|
16,429 |
|
|
|
16,003 |
|
|
|
31,299 |
|
|
|
30,535 |
|
Spain |
|
|
8,451 |
|
|
|
6,724 |
|
|
|
16,501 |
|
|
|
13,164 |
|
Israel |
|
|
— |
|
|
|
139 |
|
|
|
(0 |
) |
|
|
212 |
|
Mexico |
|
|
7,042 |
|
|
|
6,297 |
|
|
|
13,982 |
|
|
|
12,526 |
|
Other |
|
|
1,186 |
|
|
|
1,018 |
|
|
|
2,339 |
|
|
|
2,010 |
|
|
|
$ |
163,580 |
|
|
$ |
156,807 |
|
|
$ |
287,777 |
|
|
$ |
306,759 |
|
|